These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 38231271

  • 1. Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study.
    Barbanti P, Aurilia C, Egeo G, Proietti S, D'Onofrio F, Torelli P, Aguggia M, Bertuzzo D, Finocchi C, Trimboli M, Cevoli S, Fiorentini G, Orlando B, Zucco M, Di Clemente L, Cetta I, Colombo B, di Poggio MLB, Favoni V, Grazzi L, Salerno A, Carnevale A, Robotti M, Frediani F, Altamura C, Filippi M, Vernieri F, Bonassi S, ERT; for the Italian Migraine Registry study group.
    J Neurol; 2024 May; 271(5):2434-2443. PubMed ID: 38231271
    [Abstract] [Full Text] [Related]

  • 2. Impact of multiple treatment cycles with anti-CGRP monoclonal antibodies on migraine course: focus on discontinuation periods. Insights from the multicenter, prospective, I-GRAINE study.
    Barbanti P, Aurilia C, Egeo G, Proietti S, Torelli P, d'Onofrio F, Carnevale A, Tavani S, Orlando B, Fiorentini G, Colombo B, Filippi M, Bonassi S, Cevoli S, Italian Migraine Registry (I-GRAINE) study group.
    J Neurol; 2024 May; 271(5):2605-2614. PubMed ID: 38342785
    [Abstract] [Full Text] [Related]

  • 3. Late Response to Anti-CGRP Monoclonal Antibodies in Migraine: A Multicenter Prospective Observational Study.
    Barbanti P, Aurilia C, Egeo G, Torelli P, Proietti S, Cevoli S, Bonassi S, Italian Migraine Registry study group.
    Neurology; 2023 Sep 12; 101(11):482-488. PubMed ID: 37072224
    [Abstract] [Full Text] [Related]

  • 4. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study.
    Vernieri F, Brunelli N, Messina R, Costa CM, Colombo B, Torelli P, Quintana S, Cevoli S, Favoni V, d'Onofrio F, Egeo G, Rao R, Filippi M, Barbanti P, Altamura C.
    J Headache Pain; 2021 Dec 18; 22(1):154. PubMed ID: 34922444
    [Abstract] [Full Text] [Related]

  • 5. Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world.
    Caronna E, Gallardo VJ, Egeo G, Vázquez MM, Castellanos CN, Membrilla JA, Vaghi G, Rodríguez-Montolio J, Fabregat Fabra N, Sánchez-Caballero F, Jaimes Sánchez A, Muñoz-Vendrell A, Oliveira R, Gárate G, González-Osorio Y, Guisado-Alonso D, Ornello R, Thunstedt C, Fernández-Lázaro I, Torres-Ferrús M, Alpuente A, Torelli P, Aurilia C, Pére RL, Castrillo MJR, Icco R, Sances G, Broadhurst S, Ong HC, García AG, Campoy S, Sanahuja J, Cabral G, Beltrán Blasco I, Waliszewska-Prosół M, Pereira L, Layos-Romero A, Luzeiro I, Dorado L, Álvarez Escudero MR, May A, López-Bravo A, Martins IP, Sundal C, Irimia P, Lozano Ros A, Gago-Veiga AB, Juanes FV, Ruscheweyh R, Sacco S, Cuadrado-Godia E, García-Azorín D, Pascual J, Gil-Gouveia R, Huerta-Villanueva M, Rodriguez-Vico J, Viguera Romero J, Obach V, Santos-Lasaosa S, Ghadiri-Sani M, Tassorelli C, Díaz-de-Terán J, Díaz Insa S, Oria CG, Barbanti P, Pozo-Rosich P, EUREkA study group.
    J Neurol Neurosurg Psychiatry; 2024 Sep 17; 95(10):927-937. PubMed ID: 38777579
    [Abstract] [Full Text] [Related]

  • 6. Comparative effectiveness and tolerability of calcitonin gene-related peptide (CGRP) monoclonal antibodies and onabotulinumtoxinA in chronic migraine: A multicenter, real-world study in Taiwan.
    Wang YF, Yang FC, Chen LA, Chang TY, Su HC, Yang CP, Tu YH, Tzeng YS, Chen SP, Fuh JL, Lai KL, Ling YH, Chen WT, Wang SJ.
    Eur J Neurol; 2024 Sep 17; 31(9):e16372. PubMed ID: 38837528
    [Abstract] [Full Text] [Related]

  • 7. Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients.
    Barbanti P, Egeo G, Aurilia C, Altamura C, d'Onofrio F, Finocchi C, Albanese M, Aguggia M, Rao R, Zucco M, Frediani F, Filippi M, Messina R, Cevoli S, Carnevale A, Fiorentini G, Messina S, Bono F, Torelli P, Proietti S, Bonassi S, Vernieri F, Italian Migraine Registry study group.
    J Headache Pain; 2022 Nov 01; 23(1):138. PubMed ID: 36316648
    [Abstract] [Full Text] [Related]

  • 8. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
    Barbanti P, Aurilia C, Cevoli S, Egeo G, Fofi L, Messina R, Salerno A, Torelli P, Albanese M, Carnevale A, Bono F, D'Amico D, Filippi M, Altamura C, Vernieri F, EARLY Study Group.
    Headache; 2021 Oct 01; 61(9):1351-1363. PubMed ID: 34309862
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.
    De Icco R, Vaghi G, Allena M, Ghiotto N, Guaschino E, Martinelli D, Ahmad L, Corrado M, Bighiani F, Tanganelli F, Bottiroli S, Cammarota F, Sances G, Tassorelli C.
    J Headache Pain; 2022 Sep 17; 23(1):123. PubMed ID: 36115947
    [Abstract] [Full Text] [Related]

  • 11. An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor.
    Schiano di Cola F, Bolchini M, Ceccardi G, Caratozzolo S, Liberini P, Rao R, Padovani A.
    Eur J Neurol; 2023 Jun 17; 30(6):1764-1773. PubMed ID: 36856538
    [Abstract] [Full Text] [Related]

  • 12. Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study.
    Barbanti P, Egeo G, Aurilia C, Torelli P, Finocchi C, d'Onofrio F, d'Onofrio L, Rao R, Messina S, Di Clemente L, Ranieri A, Autunno M, Sette G, Colombo B, Carnevale A, Aguggia M, Tasillo M, Zoroddu F, Frediani F, Filippi M, Tomino C, Proietti S, Bonassi S, FRIEND-Study Group.
    J Headache Pain; 2023 Mar 23; 24(1):30. PubMed ID: 36949388
    [Abstract] [Full Text] [Related]

  • 13. Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study.
    Barbanti P, Aurilia C, Egeo G, Fofi L, Cevoli S, Colombo B, Filippi M, Frediani F, Bono F, Grazzi L, Salerno A, Mercuri B, Carnevale A, Altamura C, Vernieri F.
    Headache; 2021 Feb 23; 61(2):363-372. PubMed ID: 33337544
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Refractory migraine profile in CGRP-monoclonal antibodies scenario.
    Silvestro M, Tessitore A, Scotto di Clemente F, Battista G, Tedeschi G, Russo A.
    Acta Neurol Scand; 2021 Sep 23; 144(3):325-333. PubMed ID: 34019304
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan.
    Suzuki K, Suzuki S, Shiina T, Tatsumoto M, Fujita H, Haruyama Y, Hirata K.
    Cephalalgia; 2023 May 23; 43(5):3331024231177649. PubMed ID: 37231663
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Berman G, Croop R, Kudrow D, Halverson P, Lovegren M, Thiry AC, Conway CM, Coric V, Lipton RB.
    Headache; 2020 Sep 23; 60(8):1734-1742. PubMed ID: 32799325
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.